Sunday, 08 December 2024


Australia's Telix spins off Rhine Pharma to expand global access to radiopharmaceuticals

23 October 2024 | News

Rhine Pharma formed following a collaboration between Telix and Heidelberg University Hospital

Australia-based Telix Pharmaceuticals has announced the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (99mTc) and rhenium-188 (188Re).

Rhine Pharma was formed following a collaboration between Telix and Heidelberg University Hospital (UKHD), which aimed to develop a PSMA-targeting small molecule that could be labelled with either 99mTc for SPECT imaging, or 188Re for radioligand therapy.
 
The collaboration successfully created a potential next-generation theranostic compound, RHN001, which Rhine Pharma is now advancing into a novel Phase I/IIa theranostic clinical study (the 'RHINO Trial'), exploring the safety profile and efficacy of both 99mTc-RHN001 and 188Re-RHN001 in patients with advanced prostate cancer.

Because 99mTc and 188Re can each be produced using on-site generators, they enable a highly-differentiated solution for regions with limited radiopharmaceutical manufacturing infrastructure or dispersed populations. 99mTc enables imaging of patients with widely available SPECT scanners, while 188Re has demonstrated potential as a therapeutic isotope, thanks to its high-energy beta emission that maximises damage to tumour cells. Its short half-life (16.9 hours) also has the potential to simplify patient workflows in busy treatment centres with high patient demand or limited nuclear waste management capabilities.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account